Perspective Therapeutics Inc Stock Price, News & Analysis

Perspective Therapeutics (NYSE: CATX) reported key developments for Q1 2025 and provided updates on their clinical pipeline. The company is advancing three clinical-stage radiopharmaceutical therapies: 1. VMT-α-NET: 40 patients enrolled through April 2025 in Phase 1/2a trial for neuroendocrine tumors, with data accepted for ASCO presentation. 2. VMT01: First patients treated with new monotherapy dose and in combination with nivolumab for melanoma treatment. 3. PSV359: Achieved first-in-human dosing for FAP-α targeting therapy for solid tumors. The company is expanding U.S. manufacturing capabilities with two operational facilities and three additional sites under development. Financial position remains strong with $212M in cash and equivalents as of March 31, 2025, expected to fund operations into late 2026. Recent patent allowances strengthen their intellectual property portfolio through 2041-2044.

Perspective Therapeutics (NYSE: CATX), a radiopharmaceutical company focused on advanced cancer treatments, announced its participation in two major healthcare investor conferences in May 2025. The company's senior leadership will be available for one-on-one meetings with investors at both events.

The first appearance will be at the Bank of America Global Healthcare Conference in Las Vegas on May 13, featuring a 15-minute fireside chat at 11:35 a.m. PT. The second presentation will be at the 2025 RBC Capital Markets Global Healthcare Conference in New York on May 20, with a 25-minute fireside chat scheduled for 3:05 p.m. ET.

Perspective Therapeutics (NYSE: CATX) has reached a significant milestone in cancer treatment by dosing the first patient with [212Pb]PSV359 in a Phase 1/2a trial. The study focuses on patients with solid tumors expressing fibroblast activation protein alpha (FAP-α).

The trial aims to evaluate both safety and preliminary anti-tumor activity of this radiopharmaceutical treatment. Patient selection is conducted through SPECT imaging using [203Pb]PSV359. The therapy targets FAP-α, which is present on certain tumors and stromal cells within the tumor microenvironment.

Key developments include:

• Testing [212Pb]PSV359 as both monotherapy and potential combination treatment
• Optimized design for tumor uptake and retention
• Enhanced binding affinity to FAP-α
• Rapid clearance from healthy tissues

This advancement represents Perspective's commitment to developing innovative radiopharmaceutical treatments for various cancers throughout the body.

Perspective Therapeutics (NYSE AMERICAN: CATX) has announced the acceptance of two presentations featuring their radiopharmaceutical programs at the 2025 ASCO Annual Meeting in Chicago (May 30-June 3, 2025).

The presentations will showcase data from two key programs:

• An oral presentation by Thorvardur Halfdanarson on [212Pb]VMT-α-NET therapy for neuroendocrine tumors (NETs), featuring one-year follow-up data on dose-limiting toxicity and preliminary expansion results
• A poster presentation by Zachary Morris discussing interim safety and efficacy data of [212Pb]VMT01 in melanoma treatment

ASCO will release additional abstract details on May 22, 2025, at 5:00 PM EDT.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on developing advanced cancer treatments, has scheduled the release of its first quarter 2025 financial results for Monday, May 12, 2025, after market close. The company will also provide a business update at that time. The financial report and business highlights will be accessible through the newsroom section of Perspective's website.

Perspective Therapeutics (NYSE: CATX) has announced the dosing of the first patient in a new cohort of their Phase 1/2a trial evaluating [212Pb]VMT01, a targeted alpha-particle therapy for melanoma patients with positive MC1R imaging scans. The new cohort receives a 1.5 mCi monotherapy dose.

The trial expansion follows encouraging initial monotherapy results presented at the Society for Melanoma Research Congress in October 2024. Notably, this cohort includes patients with brain metastases, supported by previous imaging data showing tracer uptake in brain lesions. A parallel cohort combining [212Pb]VMT01 with nivolumab began in March 2025.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on pioneering advanced cancer treatments, has announced its participation in two major investor conferences this April.

The company will attend the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, offering one-on-one meetings with investors. Additionally, they will present at the Stifel Virtual Targeted Conference Forum on April 8, 2025, from 3:30-3:55 p.m. ET. Both events will be held virtually.

Perspective Therapeutics (NYSE: CATX) provided its full year 2024 results and business highlights, reporting strong progress across its clinical programs. The company maintains a robust cash position of $227 million as of December 31, 2024, expected to fund operations into late 2026.

Key developments include:

• VMT-α-NET trial enrolled 30 patients through February 2025 in Cohort 2, with promising early safety and efficacy data
• First-in-human combination dosing of VMT01 with nivolumab achieved in March 2025
• IND clearance received for PSV359 targeting FAP-α, with first patient dosing expected mid-2025
• Expansion of manufacturing capabilities through facility acquisitions in Houston, Chicago, and Los Angeles for $20.7 million
• €49.0 million equipment and services agreement with Comecer SpA for production facilities

Perspective Therapeutics (NYSE AMERICAN: CATX) has announced the dosing of the first patient in a new cohort of their Phase 1/2a trial combining [212Pb]VMT01, their targeted alpha-particle therapy (TAT), with Bristol Myers Squibb's nivolumab (Opdivo®) for MC1R-positive metastatic melanoma patients.

The new cohort will receive [212Pb]VMT01 at 1.5 mCi alongside nivolumab, following earlier cohorts where [212Pb]VMT01 was administered as monotherapy. Initial results from previous cohorts, presented at the Society for Melanoma Research Congress in October 2024, showed promising outcomes with:

• No dose-limiting toxicities observed
• Early signs of anti-tumor activity in heavily pretreated patients

The company aims to explore how lower-dose radiopharmaceuticals can be optimized when combined with immunotherapies to potentially enhance both safety and efficacy for patients with treatment options.